Sohail Asma, Anders Katherine L, McGuinness Sarah L, Leder Karin
School of Public Health and Preventive Medicine, Monash University, 553 St Kilda Road, Melbourne, Victoria 3004, Australia.
Infectious Diseases Department, Grampians Health Service, 1 Drummond Street North, Ballarat, Victoria 3350, Australia.
J Travel Med. 2024 Mar 1;31(2). doi: 10.1093/jtm/taae014.
Dengue is the most important arboviral disease globally and poses ongoing challenges for control including in non-endemic countries with competent mosquito vectors at risk of local transmission through imported cases. We examined recent epidemiological trends in imported and locally acquired dengue in Australia, where the Wolbachia mosquito population replacement method was implemented throughout dengue-prone areas of northern Queensland between 2011 and 2019.
We analysed dengue cases reported to the Australian National Notifiable Disease Surveillance System between January 2012 and December 2022, and Australian traveller movement data.
Between 2012 and 2022, 13 343 dengue cases were reported in Australia (median 1466 annual cases); 12 568 cases (94.2%) were imported, 584 (4.4%) were locally acquired and 191 (1.4%) had no origin recorded. Locally acquired cases decreased from a peak in 2013 (n = 236) to zero in 2021-22. Annual incidence of imported dengue ranged from 8.29/100 000 (n = 917 cases) to 22.10/100 000 (n = 2203) annual traveller movements between 2012 and 2019, decreased in 2020 (6.74/100 000 traveller movements; n = 191) and 2021 (3.32/100 000 traveller movements; n = 10) during COVID-19-related border closures, then rose to 34.79/100 000 traveller movements (n = 504) in 2022. Imported cases were primarily acquired in Southeast Asia (n = 9323; 74%), Southern and Central Asia (n = 1555; 12%) and Oceania (n = 1341; 11%). Indonesia (n = 5778; 46%) and Thailand (n = 1483; 12%) were top acquisition countries. DENV-2 (n = 2147; 42%) and DENV-1 (n = 1526; 30%) were predominant serotypes.
Our analysis highlights Australia's successful control of locally acquired dengue with Wolbachia. Imported dengue trends reflect both Australian travel destinations and patterns and local epidemiology in endemic countries.
登革热是全球最重要的虫媒病毒病,对疾病控制构成持续挑战,包括在存在本地传播风险的非流行国家,这些国家有具备传播能力的蚊媒,可能通过输入病例引发本地传播。我们研究了澳大利亚输入性和本地感染登革热的近期流行病学趋势,2011年至2019年期间,澳大利亚昆士兰州北部登革热高发地区实施了沃尔巴克氏体蚊群替代方法。
我们分析了2012年1月至2022年12月期间向澳大利亚国家法定传染病监测系统报告的登革热病例,以及澳大利亚旅行者流动数据。
2012年至2022年期间,澳大利亚共报告13343例登革热病例(年病例数中位数为1466例);12568例(94.2%)为输入性病例,584例(4.4%)为本地感染病例,191例(1.4%)病例来源未记录。本地感染病例从2013年的峰值(n = 236)降至2021 - 2022年的零例。2012年至2019年期间,输入性登革热的年发病率为每10万旅行者8.29例(n = 917例)至22.10例(n = 2203例),在2020年(每10万旅行者6.74例;n = 191例)和2021年(每10万旅行者3.32例;n = 10例)因与新冠疫情相关的边境关闭而下降,然后在2022年升至每10万旅行者34.79例(n = 504例)。输入性病例主要在东南亚感染(n = 9323;74%)、南亚和中亚(n = 1555;12%)以及大洋洲(n = 1341;11%)。印度尼西亚(n = 5778;46%)和泰国(n = 1483;12%)是主要感染国家。登革热病毒2型(DENV - 2,n = 2147;42%)和登革热病毒1型(DENV - 1,n = 1526;30%)是主要血清型。
我们的分析突出了澳大利亚通过沃尔巴克氏体成功控制本地感染登革热的情况。输入性登革热趋势既反映了澳大利亚的旅行目的地和模式,也反映了流行国家的本地流行病学情况。